GO:0050858 negative regulation of antigen receptor-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050858 describes any process that stops, prevents, or reduces signaling initiated by antigen receptor cross-linking on B or T cells.
• Key inhibitory receptors such as CD5, PD-1, and LILRB recruit phosphatases like SHP-1 to dampen antigen receptor signals [1,3,4].
• CD5-mediated negative regulation in B-1 B cells is a classic example, acting via Lyn kinase and SHP-1 [4,7,8].
• Dysregulation of this process contributes to autoimmunity, immunodeficiency, and lymphoid malignancies [1,4,8].
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of these regulatory circuits.
• Understanding this pathway informs immunotherapy, vaccine design, and treatment of allergic and autoimmune diseases [1,3,6].
Description
Antigen receptor-mediated signaling is essential for adaptive immunity, but it must be tightly controlled to prevent excessive or misdirected responses. GO:0050858, negative regulation of antigen receptor-mediated signaling pathway, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of signaling pathways initiated by cross-linking of an antigen receptor on a B or T cell. This regulation is critical for maintaining immune homeostasis and self-tolerance [1,4]. Inhibitory receptors such as CD5 and PD-1 play central roles by recruiting phosphatases that counteract activating kinases [1,4]. In B-1 B cells, CD5 constitutively associates with SHP-1 to suppress B cell receptor (BCR) signaling, a mechanism that limits autoreactivity [4,7,8]. Similarly, PD-1 engagement by its ligands leads to negative regulation of lymphocyte activation. These pathways are not merely brakes; they shape the quality and duration of immune responses. Researchers study GO:0050858 to understand how immune cells avoid overactivation, how tumors evade immunity, and how to design better immunotherapies [1,3]. The term also intersects with Toll-like receptor signaling, as negative regulators like Tollip and SLAP modulate overlapping pathways [2,5,6]. Thus, GO:0050858 represents a convergence point for immune regulation, with broad implications for health and disease.
negative regulation of antigen receptor-mediated signaling pathway At A Glance
| GO ID | GO:0050858 |
|---|---|
| GO term | negative regulation of antigen receptor-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | down regulation of antigen receptor-mediated signaling pathway; inhibition of antigen receptor-mediated signaling pathway |
| Major function | Suppression of BCR/TCR signaling to prevent excessive immune activation |
| Key regulators | CD5, PD-1, SHP-1, Lyn, LILRB, SLAP |
| Cellular context | B cells, T cells, and other antigen-presenting cells |
| Disease relevance | Autoimmunity, immunodeficiency, lymphoma, allergy |
What Is GO:0050858?
GO:0050858 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B- or T cell. In simpler terms, it covers all molecular events that put the brakes on antigen receptor signaling, ensuring that immune cell activation is kept in check.
Why Is negative regulation of antigen receptor-mediated signaling pathway Important in Cell Biology?
GO:0050858 is vital because unchecked antigen receptor signaling can lead to autoimmunity, chronic inflammation, and lymphoma, while excessive suppression can cause immunodeficiency. Understanding this process provides insights into immune tolerance, immunotherapy resistance, and the design of targeted treatments for immune-related disorders [1,3,4].
• Prevents autoimmunity by limiting autoreactive B and T cell activation [4,8].
• Modulates the duration and intensity of immune responses to pathogens.
• Influences the efficacy of cancer immunotherapy, as PD-1 is a key negative regulator.
• Dysregulation is linked to B-1 cell malignancies and chronic lymphocytic leukemia.
• Plays a role in allergic responses through FcεRI regulation by SLAP.
• Provides targets for treating autoimmune diseases like lupus and rheumatoid arthritis.
• Helps explain mechanisms of immune evasion in tumors.
• Guides vaccine design by balancing activation and inhibition [1,4].
• Informs development of checkpoint inhibitors and agonists [1,3].
• Offers biomarkers for immune disorders and therapeutic monitoring [4,8].
What Happens During negative regulation of antigen receptor-mediated signaling pathway?
Initiation by Inhibitory Receptors
In simple terms: Inhibitory receptors on the cell surface get activated and start the braking process.
Negative regulation often begins when inhibitory receptors such as CD5 or PD-1 engage their ligands or are constitutively associated with signaling molecules. For example, CD5 on B-1 B cells constitutively associates with SHP-1, a phosphatase that dampens BCR signaling. PD-1 engagement by B7 family members leads to negative regulation of lymphocyte activation. These receptors recruit phosphatases to the vicinity of the antigen receptor, setting the stage for signal attenuation.
Recruitment of Phosphatases
In simple terms: Braking molecules called phosphatases are brought in to remove activating phosphate tags.
Upon activation, inhibitory receptors recruit phosphatases such as SHP-1 via immunoreceptor tyrosine-based inhibitory motifs (ITIMs). CD5 associates with SHP-1 in B-1 cells, and this interaction is critical for negative regulation of antigen receptor-mediated signaling. Similarly, LILRB receptors recruit SHP-1 and SHP-2 to modulate myeloid cell function. These phosphatases counteract the activating kinases of the antigen receptor pathway.
Dephosphorylation of Key Signaling Intermediates
In simple terms: The phosphatases remove phosphate groups from key signaling proteins, turning off the signal.
SHP-1 dephosphorylates multiple substrates in the BCR or TCR signaling cascade, including Syk, PLCγ, and PI3K, thereby reducing calcium flux and downstream activation. In B-1 cells, CD5-mediated negative regulation involves Lyn kinase activity, which may phosphorylate ITIMs to recruit SHP-1. This dephosphorylation leads to diminished activation of transcription factors like NF-κB and NFAT.
Modulation by Other Negative Regulators
In simple terms: Other molecules like SLAP and Tollip also help put the brakes on related immune signals.
Beyond CD5 and PD-1, proteins such as SLAP negatively regulate FcεRI receptor-mediated signaling in allergic responses. Tollip negatively regulates Toll-like receptor-mediated signaling, which can intersect with antigen receptor pathways. Modulation of Toll-interleukin 1 receptor mediated signaling also involves negative regulators that may cross-talk with antigen receptor signaling. These additional layers ensure robust control of immune activation.
Downstream Consequences
In simple terms: The signal is reduced, leading to less immune cell activation and proliferation.
The ultimate outcome of negative regulation is reduced proliferation, cytokine production, and effector function of B and T cells. In B-1 B cells, CD5-mediated negative regulation of antigen receptor-induced growth signals prevents excessive expansion. This process is crucial for maintaining self-tolerance and preventing autoimmunity. Dysregulation can lead to pathological conditions such as lymphoma or autoimmune diseases [4,8].
Key Genes Involved in GO:0050858 negative regulation of antigen receptor-mediated signaling pathway
The following genes and proteins are central to the negative regulation of antigen receptor-mediated signaling pathway, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD5 | Constitutively associates with SHP-1 to inhibit BCR signaling in B-1 cells | Model for B-1 cell autoimmunity and leukemia [4,7,8] |
| PDCD1 (PD-1) | Inhibitory receptor that negatively regulates lymphocyte activation upon ligand binding | Target for cancer immunotherapy |
| PTPN6 (SHP-1) | Protein tyrosine phosphatase recruited by inhibitory receptors to dephosphorylate signaling intermediates | Central effector of negative regulation |
| LYN | Src-family kinase that phosphorylates ITIMs and modulates inhibitory signaling | Key mediator in B-1 cells |
| LILRB1-5 | Inhibitory receptors that recruit SHP-1/2 to regulate myeloid cell maturation | Regulation of myeloid function and cancer |
| SLA2 (SLAP) | Negative regulator of FcεRI receptor-mediated signaling and allergic response | Allergy and mast cell research |
| TOLLIP | Negative regulator of Toll-like receptor-mediated signaling | Innate immune regulation |
| PTPN11 (SHP-2) | Phosphatase recruited by LILRB to modulate signaling | Myeloid cell regulation |
| CD72 | Inhibitory receptor on B cells that recruits SHP-1 | B cell tolerance |
| FcγRIIB | Inhibitory Fc receptor that dampens BCR signaling | Autoimmunity models |
| SHIP-1 | Inositol phosphatase that hydrolyzes PIP3 to limit BCR signaling | B cell anergy |
| CBL | E3 ubiquitin ligase that downregulates antigen receptors | Receptor internalization |
| DOK-1 | Docking protein that recruits inhibitory molecules | T cell signaling |
| GRAIL | E3 ubiquitin ligase that negatively regulates TCR signaling | T cell tolerance |
| STIM1 | Calcium sensor that can modulate sustained signaling | T cell activation |
| SOCS1 | Suppressor of cytokine signaling that can cross-regulate antigen receptor pathways | Immune regulation |
| TRAF3 | Negative regulator of NF-κB in B cells | B cell survival |
How Is negative regulation of antigen receptor-mediated signaling pathway Regulated?
The negative regulation of antigen receptor-mediated signaling is itself tightly regulated. Inhibitory receptors are expressed in a cell-type-specific manner, and their ligands (e.g., PD-L1) can be induced by inflammatory signals. Phosphatase activity is controlled by phosphorylation and localization. For instance, SHP-1 activity is modulated by its SH2 domains binding to ITIMs. Lyn kinase activity is required for CD5-mediated negative regulation in B-1 cells. Additionally, ubiquitination and degradation of signaling components by E3 ligases like CBL provide another layer of control. Cross-talk with Toll-like receptor pathways via Tollip and SLAP further integrates signals [2,6].
negative regulation of antigen receptor-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDCD1 | Autoimmunity, cancer immunotherapy | PD-1 knockout mice, overexpression in T cells |
| CD5 | B-1 cell lymphoma, autoimmunity | CD5 knockout B cells, knock-in of mutant CD5 |
| PTPN6 | Autoimmunity, immunodeficiency | SHP-1 point mutation (motheaten mice) |
| LILRB | Myeloid leukemia, immune evasion | LILRB knockout in myeloid cells |
| SLA2 | Allergy | SLAP knockout mast cells |
Autoimmunity
Defects in negative regulation of antigen receptor signaling can lead to autoimmunity. CD5-mediated inhibition of BCR signaling in B-1 cells is crucial for preventing autoreactive responses; loss of this regulation is associated with autoimmune diseases [4,8]. PD-1 deficiency in mice causes lupus-like autoimmune disease, highlighting its role in maintaining tolerance.
Cancer
Tumors exploit negative regulatory pathways to evade immune attack. PD-1 engagement by PD-L1 on tumor cells inhibits T cell activation, and blockade of this interaction is a cornerstone of cancer immunotherapy. LILRB receptors also modulate myeloid cell function in the tumor microenvironment, contributing to immune suppression.
Allergy
SLAP negatively regulates FcεRI receptor-mediated signaling in mast cells, and its dysregulation can exacerbate allergic responses. Understanding this pathway may lead to new treatments for allergies.
Immunodeficiency
Excessive negative regulation can cause immunodeficiency by blunting protective immune responses. For example, overactive PD-1 signaling in chronic infections leads to T cell exhaustion.
From negative regulation of antigen receptor-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CD5 inhibit BCR signaling in B-1 cells? | CD5 knockout mice or B-1 cell lines |
| What is the role of SHP-1 in PD-1 signaling? | SHP-1 point mutation knock-in in T cells |
| How does LILRB modulate myeloid function? | LILRB overexpression in myeloid cell lines |
| Can SLAP suppress allergic responses? | SLAP knockout mouse model |
| Does Tollip cross-regulate antigen receptor signaling? | Tollip knockout B cells |
| What is the effect of PD-1 overexpression? | PD-1 overexpression in T cells |
How to Study the negative regulation of antigen receptor-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for negative regulation | Identify novel regulators of BCR signaling |
| Phosphoproteomics | Phosphorylation changes | Map SHP-1 substrates |
| Flow cytometry | Calcium flux, phospho-proteins | Assess BCR signaling strength |
| RNA-seq | Transcriptional changes | Downstream effects of PD-1 engagement |
| Co-immunoprecipitation | Protein-protein interactions | Detect CD5-SHP-1 association |
| FRET/BRET | Real-time signaling dynamics | Monitor inhibitory receptor activation |
| CRISPR activation (CRISPRa) | Overexpression of negative regulators | Test if overexpression dampens signaling |
| Proximity ligation assay | In situ protein interactions | Visualize ITIM-phosphatase complexes |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses antigen receptor signaling. For example, knocking out CD5 or PTPN6 would be expected to increase BCR signaling, validating their roles.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics can quantify changes in phosphorylation of signaling intermediates upon activation of inhibitory receptors. This approach can reveal direct substrates of SHP-1 in antigen receptor pathways.
Flow Cytometry and Imaging
Flow cytometry can measure calcium flux, phosphorylation of signaling proteins, and activation markers in B or T cells. Imaging can visualize co-localization of inhibitory receptors with phosphatases at the immune synapse [4,7].
RNA-seq and Transcriptomics
RNA sequencing can identify gene expression changes downstream of negative regulation, such as reduced cytokine production or altered survival genes. This helps link signaling to functional outcomes.
How CRISPR Can Be Used to Study GO:0050858 negative regulation of antigen receptor-mediated signaling pathway
Knockout
CRISPR knockout of genes like CD5, PDCD1, or PTPN6 can abolish negative regulation, leading to enhanced antigen receptor signaling. This is useful to confirm their inhibitory roles and to model autoimmune phenotypes [4,8].
Point Mutation
Introducing point mutations in ITIMs or phosphatase domains can dissect specific interactions. For example, mutating the ITIM of CD5 prevents SHP-1 recruitment, revealing its importance.
Knock-in
Knock-in of tagged versions of inhibitory receptors (e.g., HA-tagged CD5) allows for pull-down and imaging studies. Knock-in of disease-associated mutations can model human conditions.
Overexpression
Overexpression of negative regulators such as PD-1 or SLAP can suppress antigen receptor signaling, mimicking chronic inhibition or exhaustion. This is valuable for studying immunotherapy resistance [1,6].
How EDITGENE Supports negative regulation of antigen receptor-mediated signaling pathway Research
Researchers studying negative regulation of antigen receptor-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening immune activation. EDITGENE provides comprehensive CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of antigen receptor-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of antigen receptor-mediated signaling pathway
What is GO:0050858?
GO:0050858 is a Gene Ontology term for any process that stops, prevents, or reduces signaling initiated by antigen receptor cross-linking on B or T cells.
What genes are involved in negative regulation of antigen receptor-mediated signaling pathway?
Key genes include CD5, PDCD1 (PD-1), PTPN6 (SHP-1), LYN, LILRB, SLA2 (SLAP), and TOLLIP [1,2,3,4,6,7].
How does CD5 inhibit B cell receptor signaling?
CD5 constitutively associates with SHP-1 phosphatase, which dephosphorylates signaling intermediates to dampen BCR signaling in B-1 cells [4,7].
What is the role of PD-1 in this pathway?
PD-1 is an inhibitory receptor that, upon ligand binding, negatively regulates lymphocyte activation, contributing to immune tolerance and tumor evasion.
Which diseases are linked to defects in this pathway?
Defects are linked to autoimmunity, immunodeficiency, cancer, and allergy [1,3,4,6,8].
How can CRISPR be used to study this pathway?
CRISPR knockout, knock-in, point mutation, and overexpression models can dissect gene function and causality in antigen receptor signaling [4,8].
What are the main phosphatases involved?
SHP-1 (PTPN6) and SHP-2 (PTPN11) are key phosphatases recruited by inhibitory receptors like CD5 and LILRB [3,4].
What is the role of SLAP in this pathway?
SLAP negatively regulates FcεRI receptor-mediated signaling and allergic responses, and may cross-regulate antigen receptor pathways.
How does Tollip relate to antigen receptor signaling?
Tollip negatively regulates Toll-like receptor signaling, which can intersect with antigen receptor pathways [2,5].
What experimental models are used to study this pathway?
Common models include knockout mice, CRISPR-edited cell lines, and phosphoproteomics to map signaling changes [4,7,8].
Conclusion
GO:0050858, negative regulation of antigen receptor-mediated signaling pathway, is a critical biological process that maintains immune homeostasis by preventing excessive B and T cell activation. Key regulators such as CD5, PD-1, and SHP-1 have been well characterized, and their dysfunction is linked to autoimmunity, cancer, and allergy. Advances in CRISPR genome editing and multi-omics are accelerating the discovery of new components and therapeutic targets. EDITGENE offers a comprehensive suite of CRISPR services to support mechanistic and translational research in this field.
References
- 1. Freeman GJ et al.. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.. J Exp Med 192(7):1027-34 PMID: 11015443
- 2. Zhang G et al.. 2002. Negative regulation of toll-like receptor-mediated signaling by Tollip.. J Biol Chem 277(9):7059-65 PMID: 11751856
- 3. van der Touw W et al.. 2017. LILRB receptor-mediated regulation of myeloid cell maturation and function.. Cancer Immunol Immunother 66(8):1079-1087 PMID: 28638976
- 4. Sen G et al.. 1999. Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells.. Eur J Immunol 29(10):3319-28 PMID: 10540344
- 5. Li X et al.. 2005. Modulation of Toll-interleukin 1 receptor mediated signaling.. J Mol Med (Berl) 83(4):258-66 PMID: 15662540
- 6. Sharma N et al.. 2019. SLAP Is a Negative Regulator of FcεRI Receptor-Mediated Signaling and Allergic Response.. Front Immunol 10:1020 PMID: 31156621
- 7. Ochi H et al.. 2000. Negative regulation of B cell receptor-mediated signaling in B-1 cells through CD5 and Ly49 co-receptors via Lyn kinase activity.. Int Immunol 12(10):1417-23 PMID: 11007759
- 8. Bikah G et al.. 1996. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells.. Science 274(5294):1906-9 PMID: 8943203
